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Immunologic treatment strategies are established in malignant melanoma treatment, mainly focusing on Interleukin-2 in
advanced disease and interferon alpha in the adjuvant situation. In advanced disease, therapies with IL-2, interferon and diﬀerent
chemotherapeutic agents were not associated with better patient survival in the vast majority of patients. Therefore, an overview of
novel immunological agents and combined therapeutic approaches is presented in this review, covering allogenic and autologous
vaccine strategies, dendritic cell vaccination, strategies for adoptive immunotherapy and T cell receptor gene transfer, treatment
with cytokines and monoclonal antibodies against the CTLA-4 antigen. As emerging treatment strategies are based on individual
molecular and immunological characterization of individual tumors/patients, tailored targeted drug therapies move into the
focus of treatment strategies. Multimodal combination therapies with considerable potential in altering the immune response
in malignant melanoma patients are currently emerging. As oncology moves forward into the ﬁeld of personalized therapies, a
careful molecular and immunological characterization of patients is crucial to select patients for individual targeted treatment.
1.Introduction
Surgicalremovaloftumortissueisstillthemostrelevantstep
for the prognosis in treatment of patients with malignant
melanomas. In advanced stages of the disease, systemic
therapies like chemotherapy are the only relevant treat-
ment options, whereas in the adjuvant situation therapies
with interferon alpha are commonly used. Chemotherapy
regimens lead to small percentages of objective responses
while often causing considerable side eﬀects. Adjuvant
treatment with the immunomodulating drug interferon has
also signiﬁcant side eﬀects which are especially burdensome
to the patient on long-term treatment regimens. Side eﬀects
ranging from myalgias and fever to depression are observed
and often cause treatment interruption. Additionally, the
improvement of outcome due to interferon therapy is
small. In summary, these treatment regimens require the
development of novel treatment strategies, especially for the
treatment of patients with advanced malignant melanoma.
Are we at a standstill or is treatment moving on to new
possibilities?
Immunomodulation and direct targeting of signaling
pathways in malignant melanoma are promising avenues.
Especially the immunogenicity of malignant melanoma
tumor cells is important. Spontaneous complete remission
can be observed in patients with malignant melanoma and
is mainly attributed to the immune response against the
tumor. Also an elevated frequency of spontaneous humoral
immune responses against tumor antigens was found in
melanoma patients. This interaction of the immune system
with the tumor shows a promising pathway for intervention
and incorporates all portions of the immune system. Novel
and contemporary immunomodulatory therapy strategies
for malignant melanoma patients are discussed in this
review. A key element in these novel strategies is the
identiﬁcation of suitable patients, the selection being based
on detailed immunological and molecular characterizations.
But the common basis of immunological interventions is to
restore tumor-immunity in compromised patients. Tumor-
immunityandtumor-tolerancearehoweverintricatelyinter-
woven as the evolution of an immune system required the
diﬀerentiation between “self” and “nonself”. The evolution
of the immune system induced the development of a ﬁne
tuned balance between “auto-aggressivity” and “tolerance”.
Pregnancy is an example for physiological tolerance with
multiple regulatory mechanisms involved [1, 2]. In cancer2 Journal of Oncology
patients, a tumor tolerance is usually found. The therapeutic
removal of this tumor-tolerance of course bears the risk
of inducing auto-immunity [3]. It is interesting to note,
that experiments in mice showed tumor eradication upon
depletion of regulatory T cells but also induction of auto-
immunity [4]. Another obstacle is the observation that the
immunological parameters vary at diﬀerent time points of
a tumor disease. One important hypothesis was introduced
by Burnet and Thomas 50 years ago and was termed the
“cancer immunosurveillance hypothesis”. This hypothesis
proposes an interplay between immune system and tumor
cells, whereby the immune system “shapes” tumor cells
by eliminating subpopulations of malignant cells. Based
on this hypothesis, the concept of “immunoediting” was
introduced [5–7]. “Immunoediting” is a dynamic process
that has a varying degree of inﬂuence on tumor-tolerance
and immunogenicity of tumor cells. The reconstruction
of the immunologic tumorimmunity is therefore the main
aim of current therapeutic immunomodulatory concepts,
whether these concepts are based on a single or multiple
concomitant therapies.
2. HumoralImmune Responses,
Tumor AssociatedAntigensand
Monoclonal Antibodies
An interesting aspect of immune response is the presence of
spontaneous humoral responses in tumor patients through
speciﬁc antibodies. Tumor associated antigens (TAA) are
moleculesthatareusuallyfoundontumorcells.Cancertestis
antigens represent an important group within these antigens
andaremainlyfoundduringembryonaldevelopment,intes-
ticular tissue and in cancer samples. Spontaneous humoral
immune responses against TAA have been reported for
diﬀerent tumor entities [8–14]. For malignant melanoma a
prognosticsigniﬁcanceofhumoral,respectiveauto-immune,
immune responses was found [15]. The signiﬁcance of this
ﬁnding and the actual impact of these immune responses are
currently debated [16].
Another immune intervention is the administration
of ex-vivo generated monoclonal antibodies. Therapeutic
monoclonal antibodies either act as agonists or antagonists
on surface receptors, they can induce apoptosis or they
can reduce availability of speciﬁc ligands through direct
binding. As was seen in clinical trials for the therapeutic
antibody cetuximab, antibodies can have multiplying eﬀects
even when the target molecule is not present or only
in very low concentrations, Antibody dependent cellular
cytotoxicity (ADCC) induces cellular immune responses,
whereascomplement-dependentcytotoxicity(CDC)induces
an activation of the complement cascade. Monoclonal
antibodies are commonly used in clinical routine for the
treatment of multiple tumor entities [17].
The hybridoma technology allowed the production of
monoclonal mouse antibodies in mice. Mouse antibodies
have a clear limitation for clinical application: the induction
of allergic reactions. The development of fully humanized
antibodies presented a solution to this side eﬀect. These
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Figure 1: Mechanism of CTLA-4 blockade with inhibitory anti-
bodies. CTLA-4 itself negatively regulates immune responses and
blockadeleadstoincreasedantigenspeciﬁceﬀectorTcellresponses.
humanized antibodies have a much lower risk of inducing
allergic reactions and therefore a vital for patient safety and
ensure low toxicity.
A novel mechanism of antibody treatment is the modu-
lation of the immune system without direct interaction with
the tumor. In malignant melanoma patients, two antibodies
are being studied with this indirect approach, both targeting
“Anti-cytotoxic T lymphocyte-associated antigen 4” (CTLA-
4). CTLA-4 receptors in combination with the B7 molecule
andtheligandCD28onTcellsareinvolvedintheabrogation
of an immune response (see Figure 1), for example, after the
successful prevention of an infection. With the interruption
of the inhibitory signaling cascade a reversal of peripheral
tumor-tolerance can be induced, leading to the induction of
animmuneresponseagainstthetumor[18].Twohumanized
monoclonal antibodies against CTLA-4 are currently being
investigated in clinical trials: ipilimumab (MDX-010) [19]
and tremelimumab (CP-675,206) [20].
Ipilimumab has shown eﬃcacy as single agent and in
combination with chemotherapy or vaccination in patients
with metastatic malignant melanoma. Similar results were
seen for tremelimumab. There was, however, a recent trial
that showed no beneﬁt for tremelimumab compared to
chemotherapy as ﬁrst-line treatment [21]. Despite these
contradictory observations, the selective inhibition of the
CTLA-4 receptor with monoclonal antibodies is seen as an
interesting treatment strategy for patients with advanced
malignant melanomas. It is here also important to identify
predictive marker to identify patients who will beneﬁt from
that treatment. An analysis in patients treated with ipili-
mumab indicated a possible predictive role for the absoluteJournal of Oncology 3
lymphocyte count [22]. Another novel antibody is directed
against CD137 (syn. inducible receptor-like protein 4-1BB).
CD137 is expressed on CD4 and CD8 positive T cells upon
activation and induces further proliferation and activation.
Animal models showed an induced anti-tumor immune
response after administration of this antibody. Clinical phase
I trials were successful and this antibody is currently used
in a phase II clinical trial for advanced malignant melanoma
patients after conventional pretreatment.
The immunomodulatory trials pose a new problem with
regard to the evaluation of treatment response. Unlike con-
ventional chemotherapy treatment regimens, immunomod-
ulatory drugs or vaccines can show an initial worsening
of the clinical situation and following long lasting beneﬁts
[23]. This special “bi-phasic” clinical course as a result
of immunological interventions is not reﬂected in current
staging protocols or oncological practice. Criteria for the
treatment evaluation have to be revised with respect to these
observations. Additionally, antibodies can have immune
stimulating eﬀects and induce T cell responses or induce
further antibody generation, even if the antibody itself does
not have a high speciﬁcity for the tumor-associated antigen
[24, 25]. Furthermore, synergizing eﬀects of immune-based
therapy with HER-2/neu targeted vaccination and con-
comitant administration of an antiangiogenic monoclonal
antibody were observed in mouse models [26].
3. Vaccination
Vaccination strategies should ideally invoke an eﬀective T
cell response in the patient. Existing immunologic tolerance
towards the tumor should be broken by this approach.
Therefore the careful selection of usable target antigens
is important. Optimal target antigens are only expressed
homogenously within the tumor. Additionally these target
antigens should be common in the respective type of tumor
and should have high immunogenicity (see Figure 1). Diﬀer-
ent useful target antigens were identiﬁed [27]a n dh a v eb e e n
used in clinical vaccination studies [12, 28]. The majority
of established target antigens belong to the class of “cancer-
testis” antigens, which are not expressed in normal tissue
except for germ line tissue. These antigens are frequently
found in tumor tissue, for example, in multiple myeloma or
malignant melanoma. The largest group of possible target
antigens belongs however to the “diﬀerentiation antigens”.
These antigens can be found in a normal diﬀerentiated tissue
type and in the tumor arising from that tissue type. For
example, it can be found in melanocytes and in malignant
melanoma cells.
Vaccines are created in a few ways and vaccination
protocols can be based on diﬀerent strategies. Peptides of
the antigen, the whole protein or “naked” DNA can be used
for vaccination. The simultaneous use of adjuvants should
then enhance the speciﬁc T cell response. The selection of
the optimal adjuvant substance is still under investigation
in studies. All trials published so far have shown very few
side eﬀects for vaccination strategies. Hypersensitivity at the
injectionsiteandinsomecasestheinductionofautoimmune
reactionslikevitiligo(uponvaccinationwithmelanocytedif-
ferentiation antigens) were seen. So far, no major side eﬀects
were seen. Repetitious vaccinations could further enhance
speciﬁc T cell responses. Pioneering work in this ﬁeld
was done with individually generated autologous vaccines
[29]. 64 patients with metastatic malignant melanoma were
treated with autologous tumor tissue [30] and showed that
clinical and tumor-speciﬁc T cell responses could be induced
in many patients. A recent study used the autologous vaccine
Vitespen (Oncophage). Vitespen is a heatshock-protein-
peptide complex [31] that was used in a clinical trial. Results
werenotasclearcutandthereforeitremainsunclearwhether
research with Vitespen is continued. Another vaccination
strategy uses dendritic cells. Dendritic cells have a central
function in the activation of speciﬁc eﬀector T cells.
On this basis, vaccination strategies with dendritic cells
were regarded as a promising therapeutic approach even
in advanced tumor diseases [32]. Current data from trials
with dendritic cells for patients with malignant melanoma
are however not uniform. An enormous problem arises
from the variability of protocols in the preparation of
dendritic cells and in the vaccination itself. A large phase
III trial had to be stopped due to lack of eﬃcacy in the
vaccination arm. In this trial peptide-loaded autologous
dendritic cells or chemotherapy was given to patients
with advanced malignant melanoma [33]. For metastatic
malignant melanoma patients peptide-based vaccines have
not shown any clinical advantage [34]. Vaccination therapy
with little or no side eﬀects is attractive as combination
therapy for other modalities like chemotherapy or radiation
[35].Butwhyshouldacombinationbemoresuccessful?Data
on the immunological eﬀects of chemotherapy or radiation
therapy are accumulating [36–38]. During radiation the
expression of antigens on the surface of the tumor cells
is induced, while a pro-inﬂammatory microenvironment
withinthetumorispromoted. Soincombinationwithdirect
immunological approaches, the combination should lead to
greater immunological eﬀects.
Vaccination strategies have shown variable eﬃcacy in the
treatment of solid tumors [39] and appear to be unsuitable
for advanced tumor diseases [34]. It has also been proposed,
that vaccination strategies can even have detrimental eﬀects
for the patients. An important aspect in that discussion
seems to be the optimal selection of the target antigen
for clinical trials [40]. In adjuvant or minimal residual
disease treatment settings, vaccinations have shown beneﬁts
for patients. Vaccination with the tumor antigen MAGE-
A3 [41] showed for non-small cell lung cancer patients
promising results and a subsequent trial was initiated. In
malignant melanoma patients, MAGE-A3 protein was tested
as ﬁrst line therapy, showing lasting antibody responses,
strong T cell responses and clinical responses [42]. Further
trials were initiated and are ongoing. Vaccinations with the
cancer testis antigen NY-ESO-1 in “high risk” melanoma
patients have also shown encouraging results in a phase II
trial. So a clear role for vaccination has yet to be found
in the treatment of malignant melanoma patients. From
a research perspective, the interplay of antibody presence
and the activation of the immune system remain unclear
and further investigations will clearly lead to more eﬃcient4 Journal of Oncology
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Figure 2: Principle of adoptive immunotherapy.
treatment strategies. Patients at the moment should not be
treated with vaccinations outside from clinical trials.
4. Interferon and Interleukins
Interferon alpha and interleukin 2 are established immuno-
modulatingsubstancesintheroutinetreatmentofmalignant
melanoma patients. Objective response rates for interleukin
2a r e∼16%, complete remission are seen in ∼6% of the
cases. Side eﬀects of interleukin-2 treatment are severe and
treatment is usually restricted to specialized centers. Inter-
feron is used mainly in the adjuvant situation [43]. Response
rates of 10–15% have been observed, in combination with
the chemotherapy drug dacarbazine a rate of 24% can be
observed. Combination therapies with interleukin 2 and
interferon however did not increase the response rate as
compared to single agent therapy [44, 45]. The overall
survival rates have not increased with the use of interferon
and interleukin 2. In search for alternatives, interleukin
21 and 15 are investigated [46, 47]. Structural homologies
exist between interleukin 2 and interleukins 21 and 15.
The proliferation of regulatory T cells is not induced by
the latter two interleukins. As recent studies elucidated the
intratumoral cytokine milieu, the debate on useful cytokine
(or chemokine) administration in malignant melanoma
patients is likely to increase [48].
5. Adoptive Immune CellStrategies
One way to circumvent the established tumor tolerance
in tumor patients is to administer exogenous antibodies.
A similar approach on T cell level is termed “adoptive
immunotherapy”. Immune cells of the patient are activated
or primed outside of the patient and are then given back.
This intervention with ex vivo stimulation or modiﬁcation
of immune cells tries to avoid the immunosuppression or
tumortolerance in the patient. There are diﬀerent variants
of adoptive immunotherapies (see Figure 2). One possible
application is the expansion of autologous tumor-reactive
T cells, the activation and subsequent re-infusion. A pro-
tocol with extraction of tumor-inﬁltrating T cells and pre-
conditioning of the patient before re-infusion with a lym-
phodepletivechemotherapyshowedresponseratesofaround
50% [49, 50]. These results not only indicated a possible
inhibitory role of the immune system-respective the tumor
environment but also highlighted the immunomodulatory
eﬀectsofchemotherapy.Inhibitoryimmunecellsarethought
to play a key role in the chemotherapy-induced alterations
in the local tumor environment. Myeloid-derived suppressor
cells (MDSCs) and regulatory T cells inﬂuence the immune
response [4, 51]. The above mentioned study has demon-
strated the feasibility of this combined approach, some of
the patients had long lasting antigen-speciﬁc T cells, long
after the re-infusion of the expanded T cells. The population
of expanded T cells was derived from the tumor, tumor-
inﬁltrating lymphocytes (TILs). Earlier approaches with
adoptive immunotherapies using circulating lymphocytes
(lymphokine-activated killer cells, LAKs) did not yield good
clinical results. Diﬃculties with this concept can arise in
tumors where it is diﬃcult to extract lymphocytes. Immune
cell transfers can of course facilitate other immune cell
populations, like natural killer cells [52].Journal of Oncology 5
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Figure 3: T cell receptor transfer.
6. T-Cell Receptor Transfer
Another way of inducing tumor-speciﬁc immune responses
is the direct transfer of tumor-speciﬁcity to non-tumor-
speciﬁc T cells. The principle of “T cell receptor transfer”
is the retroviral transfer of speciﬁc alpha- and beta-chains
of a speciﬁc T cell receptor (TCR) (see Figure 3)[ 53].
Retroviral transfer of genetic information has risks because
with stable integration errors can occur, possibly resulting
in unwanted eﬀects. One way to ensure safety is to use
“self-destructive” vectors. Another problem that can arise
with T cell receptor transfer is the generation of chimeric T
cell receptors. Chimeric receptors have endogenous alpha-
or beta-chains mixed with the modiﬁed or transfected
ones. This can lead to unforeseen T cell speciﬁcities and
therefore lead to incalculable side eﬀects. A solution to this
problem is the use of “hybrid T cell receptors” [54]. These
T cell receptors contain murine constant regions and human
variable regions. This leads to a majority of correct pairings
and leads to other improved immunological properties.
7.TargetedPathwayInhibition
Why a section on “targeted pathway inhibition” in a review
on immunological and multimodal treatment strategies in
malignant melanoma patients? Targeted agents can alter
the proteins involved in key pathways, such as apoptotic
pathways and thereby improve, for example immunother-
apies. The detailed investigations on signaling pathways in
tumor cells lead to speciﬁc drugs for selective inhibition.
The direct inhibition of signaling pathways has already lead
to enormous improvements in other tumor entities [55,
56]. In the analyses of the eﬀects of pathway inhibition
data is accumulating that shows an eﬀect of this inhibition
on antigen presentation and tumor cell recognition [57,
58]. In malignant melanomas multiple diﬀerent abera-
tions in diﬀerent pathways are found. Upregulation of the
RAS/RAF/MEK signaling pathway [59, 60], an upregulation
of the PI3K/Akt3 pathway via a mutation of the PTEN gene
[61], a decreased expression of the retinoblastoma protein
(RB) via cyclin D1 or CDK4, activating c-Kit mutations and
inactivation of the CDKN2A gene can often be found in
melanomas. Small molecule inhibitors like sorafenib inhibit
multiple kinases, for example, B-RAF, C-RAF, VEGFR-2,
PDGFR and c-KIT, and sorafenib has shown eﬃcacy as
single agent and in combination with chemotherapy in
patients with advanced malignant melanoma. The inhibition
oftheRAS/RAF/MEK/ERKpathway(andothersliketheAkt,
PI3K, mTOR or hedghehog pathway) has more beneﬁcial
eﬀects for immunological treatments, as the expression of
anti-apoptotic proteins are downregulated. Eﬀective T cell
responses against tumor cells induce tumor cell apoptosis.
Tumor cells often develop strategies to inhibit induced
apoptosis, so that targeting of anti-apoptotic proteins in the
treatment of malignant melanoma patients can strengthen
the eﬀectiveness of the immune response [62]. The full range
of immunological eﬀects of targeted therapies has to be
investigated in future research to fully harness the potential
of these treatments.
8. Conclusion
In summary, melanoma is a unique cancer because advanced
disease can respond to immune surveillance. Working from6 Journal of Oncology
the principles of spontaneous regression and unique tumor
antigens such as the testis antigen, several principles of
immune function are now understood. In addition to the
established, albeit toxic and rather ineﬀective treatments
of interferon alpha in the adjuvant setting and Interleukin
2 in the advanced setting, new therapies with anti-CTLA-
4 antibodies or speciﬁc (individualized) tumor vaccines
are being developed. Adoptive transfer with tumor inﬁl-
trating lymphocytes may hold promise. Melanoma path-
ways are better understood and targeted therapies to the
RAF/RAS/MEK/ERK or other signaling pathways could be
combined with immune treatments. The existing results
are promising and new avenues will open with a detailed
understanding of the immunological interactions of tumor
and immune cells and the immunological eﬀects of modern
(targeted) drug therapies.
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